Harmer Catherine J, Duman Ronald S, Cowen Philip J
University Department of Psychiatry, University of Oxford, Oxford, UK.
Department of Psychiatry, Yale School of Medicine, Yale University, New Haven, CT, USA.
Lancet Psychiatry. 2017 May;4(5):409-418. doi: 10.1016/S2215-0366(17)30015-9. Epub 2017 Jan 31.
Most currently available antidepressants target monoamine neurotransmitter function. However, a purely neurotransmitter-based explanation for antidepressant drug action is challenged by the delayed clinical onset of most agents and the need to explain how neurochemical changes reverse the many different symptoms of depression. Novel approaches to understanding of antidepressant drug action include a focus on early changes in emotional and social processing and the role of neural plasticity. In this Review, we discuss the ways in which these two different theories reflect different or complementary approaches, and how they might be integrated to offer novel solutions for people with depression. We consider the predictions made by these mechanistic approaches for the stratification and development of new therapeutics for depression, and the next steps that need to be made to facilitate this translation of science to the clinic.
目前大多数可用的抗抑郁药作用于单胺神经递质功能。然而,大多数药物临床起效延迟,且需要解释神经化学变化如何逆转抑郁症的多种不同症状,这使得基于神经递质的抗抑郁药作用解释受到挑战。理解抗抑郁药作用的新方法包括关注情绪和社会加工的早期变化以及神经可塑性的作用。在本综述中,我们讨论了这两种不同理论反映不同或互补方法的方式,以及它们如何整合以为抑郁症患者提供新的解决方案。我们考虑了这些机制方法对抑郁症新疗法分层和开发的预测,以及为促进科学转化为临床应用而需要采取的后续步骤。